Altimmune, Inc.
ALT
$3.31
-$0.06-1.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.00K | 36.00K | 41.00K | 20.00K | 20.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.00K | 36.00K | 41.00K | 20.00K | 20.00K |
| Cost of Revenue | 66.71M | 66.09M | 66.43M | 67.80M | 72.65M |
| Gross Profit | -66.68M | -66.05M | -66.39M | -67.78M | -72.63M |
| SG&A Expenses | 32.04M | 30.16M | 28.10M | 22.68M | 21.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.75M | 96.25M | 94.53M | 90.48M | 94.39M |
| Operating Income | -98.72M | -96.21M | -94.49M | -90.46M | -94.37M |
| Income Before Tax | -91.76M | -91.08M | -88.77M | -84.60M | -88.43M |
| Income Tax Expenses | 0.00 | 0.00 | -681.00K | -681.00K | -681.00K |
| Earnings from Continuing Operations | -91.76 | -91.08 | -88.09 | -83.92 | -87.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.76M | -91.08M | -88.09M | -83.92M | -87.75M |
| EBIT | -98.72M | -96.21M | -94.49M | -90.46M | -94.37M |
| EBITDA | -98.62M | -96.10M | -94.38M | -90.34M | -94.24M |
| EPS Basic | -0.79 | -0.94 | -1.02 | -1.07 | -1.18 |
| Normalized Basic EPS | -0.49 | -0.58 | -0.64 | -0.67 | -0.74 |
| EPS Diluted | -0.79 | -0.94 | -1.02 | -1.07 | -1.18 |
| Normalized Diluted EPS | -0.49 | -0.58 | -0.64 | -0.67 | -0.74 |
| Average Basic Shares Outstanding | 499.94M | 395.97M | 347.06M | 317.70M | 299.37M |
| Average Diluted Shares Outstanding | 499.94M | 395.97M | 347.06M | 317.70M | 299.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |